title: A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy.
abstract: A 71-year-old woman presented with an abdominal mass and ascites and was subsequently admitted to our hospital in June 1995. Further examination revealed that the mass was malignant and, as a result, surgery was indicated. However, the mass demonstrated widespread peritoneal dissemination, which therefore could not be resected, and pathological findings suggested a malignant peritoneal mesothelioma. The patient showed a remarkable response to combined chemotherapy with an accompanying intraperitoneal injection of cisplatin and etoposide and an intravenous injection of caffeine. However, owing to side effects, this regimen was discontinued. The patient was administered a combination drug of uracil and tegafur (UFT) in addition to intraperitoneal injection of cisplatin as an outpatient. By the 223rd day after surgery, the tumor mass and ascites had completely disappeared according to the CT. Hence chemotherapy was judged to have resulted in complete remission. Such a marked response to chemotherapy is rare in an advanced malignant peritoneal mesothelioma such as the present case. Eight months later, the tumor recurred in the pleura. Another regimen of chemotherapy with cisplatin and CPT-11 was performed. However, this treatment proved ineffective. The patient subsequently died of respiratory failure in January 1997 due to the mesothelioma. This is a case report of complete remission of malignant peritoneal mesothelioma by combined chemotherapy.
authors.affiliation: First Department of Surgery, Yokohama City University, School of Medicine, Kanagawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Imada
authors.forename: J
authors.initials: J
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Amano
authors.forename: T
authors.initials: T
authors.lastname: Maehara
authors.forename: Y
authors.initials: Y
authors.lastname: Rino
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Shiozawa
authors.forename: S
authors.initials: S
authors.lastname: Hatori
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002110:Caffeine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D009382:Neoplasms, Unknown Primary / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D002110:Caffeine; D014498:Uracil; D005047:Etoposide; D002945:Cisplatin